$RPTX
Repare Therapeutics Inc.

2024 Q2 Form 10-Q Financial Statement

#000095017024054515 Filed on May 07, 2024

View on sec.gov

Income Statement

Concept 2024 Q2 2024 Q1
Revenue
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin
YoY Change
% of Gross Profit
Research & Development $30.08M $32.97M
YoY Change -10.99% 3.58%
% of Gross Profit
Depreciation & Amortization $501.0K
YoY Change 13.61%
% of Gross Profit
Operating Expenses $38.39M $41.59M
YoY Change -9.68% 3.05%
Operating Profit -$37.32M $10.82M
YoY Change 204.45% -131.19%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $2.871M $2.975M
YoY Change -16.1% -11.35%
Pretax Income -$34.45M $13.79M
YoY Change 289.86% -144.03%
Income Tax $326.0K $629.0K
% Of Pretax Income 4.56%
Net Earnings -$34.77M $13.16M
YoY Change 191.09% -137.67%
Net Earnings / Revenue
Basic Earnings Per Share -$0.82 $0.31
Diluted Earnings Per Share -$0.82 $0.30
COMMON SHARES
Basic Shares Outstanding 42.45M 42.18M
Diluted Shares Outstanding 42.45M 44.02M

Balance Sheet

Concept 2024 Q2 2024 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments
YoY Change
Cash & Equivalents $79.82M $103.2M
Short-Term Investments
Other Short-Term Assets
YoY Change
Inventory
Prepaid Expenses $5.773M $3.463M
Receivables
Other Receivables $3.571M $3.377M
Total Short-Term Assets $228.5M $254.7M
YoY Change -21.71% -21.77%
LONG-TERM ASSETS
Property, Plant & Equipment $3.226M $3.714M
YoY Change -33.08% -31.17%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $307.0K $307.0K
YoY Change -24.75% -24.75%
Total Long-Term Assets $6.805M $8.414M
YoY Change -29.58% -21.95%
TOTAL ASSETS
Total Short-Term Assets $228.5M $254.7M
Total Long-Term Assets $6.805M $8.414M
Total Assets $235.3M $263.1M
YoY Change -21.97% -21.77%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $7.182M $6.825M
YoY Change 46.78% 88.54%
Accrued Expenses
YoY Change
Deferred Revenue $0.00 $1.073M
YoY Change -100.0% -97.97%
Short-Term Debt
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $31.45M $30.57M
YoY Change -40.94% -62.23%
LONG-TERM LIABILITIES
Long-Term Debt
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $31.45M $30.57M
Total Long-Term Liabilities
Total Liabilities $31.67M $31.13M
YoY Change -43.63% -63.4%
SHAREHOLDERS EQUITY
Retained Earnings -$354.7M -$319.9M
YoY Change 23.94% 16.66%
Common Stock $558.5M $552.0M
YoY Change 4.98% 5.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $203.7M $232.0M
YoY Change
Total Liabilities & Shareholders Equity $235.3M $263.1M
YoY Change -21.97% -21.77%

Cashflow Statement

Concept 2024 Q2 2024 Q1
OPERATING ACTIVITIES
Net Income -$34.77M $13.16M
YoY Change 191.09% -137.67%
Depreciation, Depletion And Amortization $501.0K
YoY Change 13.61%
Cash From Operating Activities $11.93M
YoY Change -137.54%
INVESTING ACTIVITIES
Capital Expenditures $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities -$20.32M
YoY Change 203.86%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 375.0K
YoY Change -9.2%
NET CHANGE
Cash From Operating Activities 11.93M
Cash From Investing Activities -20.32M
Cash From Financing Activities 375.0K
Net Change In Cash -8.051M
YoY Change -78.85%
FREE CASH FLOW
Cash From Operating Activities $11.93M
Capital Expenditures $0.00
Free Cash Flow $11.93M
YoY Change -136.99%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2024Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2024Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2024Q1 dei Amendment Flag
AmendmentFlag
false
CY2024Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001808158
CY2024Q1 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
A8
CY2024Q1 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
00-0000000
CY2024Q1 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2023 us-gaap Preferred Stock Shares Authorized Unlimited
PreferredStockSharesAuthorizedUnlimited
Unlimited
CY2024Q1 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2023 us-gaap Common Stock Shares Authorized Unlimited
CommonStockSharesAuthorizedUnlimited
Unlimited
CY2024Q1 dei Document Type
DocumentType
10-Q
CY2024Q1 dei Document Quarterly Report
DocumentQuarterlyReport
true
CY2024Q1 dei Document Period End Date
DocumentPeriodEndDate
2024-03-31
CY2024Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
CY2024Q1 dei Document Transition Report
DocumentTransitionReport
false
CY2024Q1 dei Entity File Number
EntityFileNumber
001-39335
CY2024Q1 dei Entity Registrant Name
EntityRegistrantName
Repare Therapeutics Inc.
CY2024Q1 dei Entity Address Address Line1
EntityAddressAddressLine1
7171 Frederick-Banting
CY2024Q1 dei Entity Address Address Line2
EntityAddressAddressLine2
Building 2
CY2024Q1 dei Entity Address Address Line3
EntityAddressAddressLine3
Suite 270
CY2024Q1 dei Entity Address City Or Town
EntityAddressCityOrTown
St-Laurent
CY2024Q1 dei Entity Address State Or Province
EntityAddressStateOrProvince
QC
CY2024Q1 dei Entity Address Country
EntityAddressCountry
CA
CY2024Q1 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
H4S 1Z9
CY2024Q1 dei City Area Code
CityAreaCode
857
CY2024Q1 dei Local Phone Number
LocalPhoneNumber
412-7018
CY2024Q1 dei Security12b Title
Security12bTitle
Common shares, no par value
CY2024Q1 dei Trading Symbol
TradingSymbol
RPTX
CY2024Q1 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2024Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2024Q1 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2024Q1 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2024Q1 dei Entity Small Business
EntitySmallBusiness
false
CY2024Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2024Q1 dei Entity Shell Company
EntityShellCompany
false
CY2024Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
42445406
CY2024Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
103217000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
111268000
CY2024Q1 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
133784000
CY2023Q4 us-gaap Marketable Securities Current
MarketableSecuritiesCurrent
112359000
CY2024Q1 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
10829000
CY2023Q4 us-gaap Income Taxes Receivable
IncomeTaxesReceivable
10813000
CY2024Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
3377000
CY2023Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
4499000
CY2024Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3463000
CY2023Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
4749000
CY2024Q1 us-gaap Assets Current
AssetsCurrent
254670000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
243688000
CY2024Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3714000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
4215000
CY2024Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2763000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
3326000
CY2024Q1 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
1630000
CY2023Q4 us-gaap Income Taxes Receivable Noncurrent
IncomeTaxesReceivableNoncurrent
2276000
CY2024Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
307000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
396000
CY2024Q1 us-gaap Assets
Assets
263084000
CY2023Q4 us-gaap Assets
Assets
253901000
CY2024Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
6825000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2400000
CY2024Q1 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
20454000
CY2023Q4 us-gaap Accrued Liabilities And Other Liabilities
AccruedLiabilitiesAndOtherLiabilities
24057000
CY2024Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2218000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
2400000
CY2024Q1 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
1073000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
10222000
CY2024Q1 us-gaap Liabilities Current
LiabilitiesCurrent
30570000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39079000
CY2024Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
561000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1010000
CY2024Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1730000
CY2024Q1 us-gaap Liabilities
Liabilities
31131000
CY2023Q4 us-gaap Liabilities
Liabilities
41819000
CY2024Q1 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2023Q4 us-gaap Preferred Stock No Par Value
PreferredStockNoParValue
0
CY2024Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
-141000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent
193000
CY2024Q1 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2024Q1 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2023Q4 us-gaap Common Stock No Par Value
CommonStockNoParValue
0
CY2024Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42445406
CY2024Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42445406
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
42176041
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
42176041
CY2024Q1 us-gaap Common Stock Value
CommonStockValue
486375000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
483350000
CY2024Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
65638000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
61813000
CY2024Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-113000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
28000
CY2024Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-319947000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-333109000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
231953000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
212082000
CY2024Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
263084000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
253901000
CY2024Q1 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
52404000
CY2023Q1 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
5678000
CY2024Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
32970000
CY2023Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
31830000
CY2024Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8618000
CY2023Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
8529000
CY2024Q1 us-gaap Operating Expenses
OperatingExpenses
41588000
CY2023Q1 us-gaap Operating Expenses
OperatingExpenses
40359000
CY2024Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
10816000
CY2023Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-34681000
CY2024Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
31000
CY2023Q1 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-56000
CY2024Q1 us-gaap Investment Income Net
InvestmentIncomeNet
2968000
CY2023Q1 us-gaap Investment Income Net
InvestmentIncomeNet
3427000
CY2024Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
24000
CY2023Q1 us-gaap Other Nonoperating Expense
OtherNonoperatingExpense
15000
CY2024Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
2975000
CY2023Q1 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3356000
CY2024Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
13791000
CY2023Q1 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-31325000
CY2024Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
629000
CY2023Q1 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
3616000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
13162000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34941000
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-141000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
193000
CY2024Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
13021000
CY2023Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-34748000
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.3
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42234001
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42040674
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44024198
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42040674
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
279517000
CY2023Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6062000
CY2023Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2023Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
193000
CY2023Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
-34941000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
251244000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
212082000
CY2024Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6475000
CY2024Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2024Q1 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-141000
CY2024Q1 us-gaap Income Loss From Continuing Operations Including Portion Attributable To Noncontrolling Interest
IncomeLossFromContinuingOperationsIncludingPortionAttributableToNoncontrollingInterest
13162000
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
231953000
CY2024Q1 us-gaap Profit Loss
ProfitLoss
13162000
CY2023Q1 us-gaap Profit Loss
ProfitLoss
-34941000
CY2024Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6475000
CY2023Q1 us-gaap Share Based Compensation
ShareBasedCompensation
6062000
CY2024Q1 us-gaap Depreciation
Depreciation
501000
CY2023Q1 us-gaap Depreciation
Depreciation
441000
CY2024Q1 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
563000
CY2023Q1 us-gaap Provision For Loan And Lease Losses
ProvisionForLoanAndLeaseLosses
541000
CY2024Q1 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
22000
CY2023Q1 rptx Foreign Currency Transaction Gain Loss
ForeignCurrencyTransactionGainLoss
-66000
CY2024Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1245000
CY2023Q1 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
1839000
CY2024Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1286000
CY2023Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
-1330000
CY2024Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-1110000
CY2023Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
2741000
CY2024Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
CY2023Q1 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-89000
CY2024Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
4431000
CY2023Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
2016000
CY2024Q1 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-3587000
CY2023Q1 rptx Increase Decrease In Accrued Expenses And Other Current Liabilities
IncreaseDecreaseInAccruedExpensesAndOtherCurrentLiabilities
-4203000
CY2024Q1 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
-153000
CY2023Q1 rptx Increase Decrease In Operating Lease Liability Current
IncreaseDecreaseInOperatingLeaseLiabilityCurrent
35000
CY2024Q1 rptx Number Of Operating Leases
NumberOfOperatingLeases
4
CY2024Q1 us-gaap Lessee Operating Lease Existence Of Option To Terminate
LesseeOperatingLeaseExistenceOfOptionToTerminate
false
CY2024Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
630000
CY2023Q1 us-gaap Increase Decrease In Income Taxes
IncreaseDecreaseInIncomeTaxes
3616000
CY2024Q1 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-429000
CY2023Q1 rptx Increase Decrease In Operating Lease Liability Net
IncreaseDecreaseInOperatingLeaseLiabilityNet
-581000
CY2024Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-10879000
CY2023Q1 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
-1677000
CY2024Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
11932000
CY2023Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-31786000
CY2024Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
0
CY2023Q1 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
475000
CY2024Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
69015000
CY2023Q1 us-gaap Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
92500000
CY2024Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
89331000
CY2023Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
98711000
CY2024Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20316000
CY2023Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-6686000
CY2024Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
17000
CY2023Q1 us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
CY2024Q1 rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
358000
CY2023Q1 rptx Proceeds From Issuance Of Common Stock Under Two Thousand Twenty Employee Share Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderTwoThousandTwentyEmployeeSharePurchasePlan
409000
CY2024Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
375000
CY2023Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
413000
CY2024Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-42000
CY2023Q1 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-1000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-8051000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-38060000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
111268000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
159521000
CY2024Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
103217000
CY2023Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
121461000
CY2024Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0
CY2023Q1 us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
1134000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
146000
CY2024Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:18pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;"> </span></p><p style="text-indent:4.533%;font-size:10pt;margin-top:6pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the amounts reported in consolidated financial statements and accompanying notes. Significant estimates and assumptions reflected in these unaudited condensed consolidated financial statements include, but are not limited to, estimates related to revenue recognition, accrued research and development expenses, share-based compensation and income taxes. The Company bases its estimates on historical experience and other market specific or other relevant assumptions that it believes to be reasonable under the circumstances. Actual results could differ from those estimates. Estimates are periodically reviewed in light of changes in circumstances, facts and experience. Changes in estimates are recorded in the period in which they become known.</span></p>
CY2024Q1 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
400000
CY2023Q4 us-gaap Accrued Investment Income Receivable
AccruedInvestmentIncomeReceivable
400000
CY2024Q1 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
109300000
CY2023Q4 us-gaap Debt Securities Available For Sale Unrealized Loss Position
DebtSecuritiesAvailableForSaleUnrealizedLossPosition
58600000
CY2024Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2023Q1 us-gaap Debt Securities Available For Sale Allowance For Credit Loss Not Previously Recorded
DebtSecuritiesAvailableForSaleAllowanceForCreditLossNotPreviouslyRecorded
0
CY2024Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
-100000
CY2023Q1 us-gaap Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax
OtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax
200000
CY2024Q1 rptx Fair Value Assets Transfers Between All Levels
FairValueAssetsTransfersBetweenAllLevels
0
CY2023Q1 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
5678000
CY2024Q1 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
16443000
CY2023Q4 rptx Accrued Research And Development Expense Current
AccruedResearchAndDevelopmentExpenseCurrent
16251000
CY2024Q1 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2739000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
6981000
CY2024Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
671000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
631000
CY2024Q1 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
601000
CY2023Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
194000
CY2024Q1 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
20454000
CY2023Q4 rptx Accrued Expenses And Other Liabilities Current
AccruedExpensesAndOtherLiabilitiesCurrent
24057000
CY2024Q1 rptx Revenue From Collaboration Agreements
RevenueFromCollaborationAgreements
52404000
CY2024Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
594000
CY2023Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
592000
CY2024Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
19000
CY2023Q1 us-gaap Short Term Lease Cost
ShortTermLeaseCost
14000
CY2024Q1 us-gaap Variable Lease Cost
VariableLeaseCost
85000
CY2023Q1 us-gaap Variable Lease Cost
VariableLeaseCost
40000
CY2024Q1 us-gaap Lease Cost
LeaseCost
698000
CY2023Q1 us-gaap Lease Cost
LeaseCost
646000
CY2024Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
613000
CY2023Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
599000
CY2024Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2023Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
146000
CY2024Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y2M23D
CY2023Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y2M8D
CY2024Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.042
CY2023Q1 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.041
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
10097771
CY2023Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
13.77
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
1376682
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.95
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8485
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.99
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
145179
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
16.74
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
11320789
CY2024Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
12.91
CY2024Q1 us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
8485
CY2024Q1 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
1.99
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6475000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6062000
CY2024Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6475000
CY2023Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6062000
CY2024Q1 us-gaap Net Income Loss
NetIncomeLoss
13162000
CY2023Q1 us-gaap Net Income Loss
NetIncomeLoss
-34941000
CY2024Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42234001
CY2023Q1 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
42040674
CY2024Q1 rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options Restricted Shares Units And Share Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsRestrictedSharesUnitsAndShareIssuableUnderTheEspp
1790197
CY2023Q1 rptx Incremental Common Shares Attributable To Dilutive Effect Of Stock Options Restricted Shares Units And Share Issuable Under The Espp
IncrementalCommonSharesAttributableToDilutiveEffectOfStockOptionsRestrictedSharesUnitsAndShareIssuableUnderTheEspp
0
CY2024Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
44024198
CY2023Q1 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
42040674
CY2024Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
0.31
CY2023Q1 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-0.83
CY2024Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
0.3
CY2023Q1 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-0.83
CY2024Q1 ecd Rule10b51 Arr Adopted Flag
Rule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Adopted Flag
NonRule10b51ArrAdoptedFlag
false
CY2024Q1 ecd Rule10b51 Arr Trmntd Flag
Rule10b51ArrTrmntdFlag
false
CY2024Q1 ecd Non Rule10b51 Arr Trmntd Flag
NonRule10b51ArrTrmntdFlag
false

Files In Submission

Name View Source Status
0000950170-24-054515-index-headers.html Edgar Link pending
0000950170-24-054515-index.html Edgar Link pending
0000950170-24-054515.txt Edgar Link pending
0000950170-24-054515-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
img194139340_0.jpg Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
rptx-20240331.htm Edgar Link pending
rptx-20240331.xsd Edgar Link pending
rptx-ex10_1.htm Edgar Link pending
rptx-ex31_1.htm Edgar Link pending
rptx-ex31_2.htm Edgar Link pending
rptx-ex32_1.htm Edgar Link pending
Show.js Edgar Link pending
rptx-20240331_htm.xml Edgar Link completed